Waters (NYSE:WAT) Shares Acquired Rep. Julia Letlow

Representative Julia Letlow (R-Louisiana) recently bought shares of Waters Corporation (NYSE:WAT). In a filing disclosed on January 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Waters stock on December 8th. The trade occurred in the Representative’s “MERRILL LYNCH INVESTMENT ACCOUNT #025” account.

Representative Julia Letlow also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Pinterest (NYSE:PINS) on 12/16/2025.
• Purchased $1,001 – $15,000 in shares of United Rentals (NYSE:URI) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Mettler-Toledo International (NYSE:MTD) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Icon Energy (NASDAQ:ICON) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Devon Energy (NYSE:DVN) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of AstraZeneca (NASDAQ:AZN) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Warner Bros. Discovery (NASDAQ:WBD) on 12/8/2025.

Waters Price Performance

Waters stock opened at $392.82 on Thursday. The business’s 50 day simple moving average is $388.54 and its 200 day simple moving average is $339.90. Waters Corporation has a 12 month low of $275.05 and a 12 month high of $423.56. The company has a market cap of $23.39 billion, a price-to-earnings ratio of 36.11, a PEG ratio of 3.29 and a beta of 1.16. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.41.

Waters (NYSE:WAT) last issued its earnings results on Tuesday, November 4th. The medical instruments supplier reported $3.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.21 by $0.19. Waters had a return on equity of 36.59% and a net margin of 20.89%.The firm had revenue of $799.89 million for the quarter, compared to analyst estimates of $780.05 million. During the same period in the previous year, the company posted $2.93 earnings per share. The business’s revenue was up 8.1% on a year-over-year basis. Waters has set its FY 2025 guidance at 13.050-13.150 EPS and its Q4 2025 guidance at 4.450-4.550 EPS. Sell-side analysts forecast that Waters Corporation will post 12.86 EPS for the current year.

Institutional Trading of Waters

A number of hedge funds have recently made changes to their positions in the stock. Root Financial Partners LLC purchased a new position in shares of Waters in the third quarter worth about $26,000. ANTIPODES PARTNERS Ltd purchased a new stake in Waters during the 3rd quarter valued at about $26,000. Hantz Financial Services Inc. grew its position in Waters by 115.4% during the 3rd quarter. Hantz Financial Services Inc. now owns 112 shares of the medical instruments supplier’s stock worth $34,000 after acquiring an additional 60 shares during the last quarter. IFP Advisors Inc increased its stake in Waters by 65.4% in the 2nd quarter. IFP Advisors Inc now owns 134 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 53 shares during the period. Finally, CYBER HORNET ETFs LLC bought a new stake in Waters in the second quarter valued at approximately $53,000. 94.01% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on WAT. Cowen reaffirmed a “hold” rating on shares of Waters in a report on Wednesday, November 5th. Wells Fargo & Company boosted their price target on shares of Waters from $385.00 to $415.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. William Blair initiated coverage on shares of Waters in a report on Monday, January 5th. They issued an “outperform” rating for the company. Wolfe Research upgraded shares of Waters from a “peer perform” rating to an “outperform” rating and set a $480.00 price objective for the company in a research note on Wednesday, December 10th. Finally, Rothschild & Co Redburn assumed coverage on Waters in a research report on Wednesday, October 8th. They set a “buy” rating and a $390.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, Waters has an average rating of “Moderate Buy” and a consensus price target of $395.00.

About Representative Letlow

Julia Letlow (Republican Party) is a member of the U.S. House, representing Louisiana’s 5th Congressional District. She assumed office on April 14, 2021. Her current term ends on January 3, 2027.

Letlow (Republican Party) is running for re-election to the U.S. House to represent Louisiana’s 5th Congressional District. She declared candidacy for the primary scheduled on November 3, 2026.

Julia Letlow earned a doctorate. Letlow’s career experience includes working as a senior administrator with the University of Louisiana at Monroe.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.